Global Biosimilars Market which is valued close to $18 billion (2020) is growing at a Double-Digit Rate

A biosimilar is a biological product which is similar to a reference biologic with no clinically meaningful differences in terms of potency, purity, and safety.

Loss of patent protection for originator brands to drive the biosimilar market growth

A key driver of biosimilar market growth over the next 5-10 years is the number of losses of protection (LoP) events for originator brands. In the US alone, 66 biologic U.S. patents are expiring between 2020 and 2025, owing to which the biosimilar market is on the cusp of a significant boost. Oncology is one of the major therapeutic areas in biosimilars market and by 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars to enter in oncology space and propelling oncology biosimilars market.

Consistent growth in the biosimilar approvals in the US biosimilars market

The US biosimilars market is growing across multiple therapeutic areas. From 1 approval in 2015, the number of FDA approvals have increased to 10 in 2019 (only 3 approvals in 2020 impacted by COVID as shown in figure below). The steady and consistent increase in number of biosimilar approvals and market availability in US is driving the US biosimilars market growth. In 2015, only 1 biosimilar product was available for use in market and this number reached to 19 by end of 2020.

“There is a huge growth potential for biosimilar market as they deliver significant benefits to the healthcare community. Biosimilars help augment overall treatment options, positively impact patients suffering from life-threatening conditions, whilst contributing to the quality and financial sustainability of healthcare systems.” – CEO, Leading Biosimilars Company

Regional Snapshot: Global Biosimilars Market

Europe is the largest market for biosimilars owing to adoption of more liberal policies which has enabled greater market access. Whereas, United States has taken a more protective approach towards originator brands, further influenced by lobbying from pharma companies. Owing to this, the biosimilar adoption is relatively slower in US. However, the US biosimilar landscape is now evolving rapidly. There were 29 biosimilars approved in US compared to 11 in EU in the initial six years. Also, in April 2021, the US signed two bipartisan bills to reduce prescription drug prices by supporting generics/biosimilars. Such developments will fuel the growth of the US biosimilars market.

The key players working in the global biosimilars market are Amgen, Roche, Sandoz, Dr. Reddy’s, Teva, Pfizer, Eli Lilly, Samsung, Biocon, Boehringer, and Mylan.

Explore Detailed Insights on Global Biosimilars Market @ https://meditechinsights.com/global-biosimilars-market/

Comments

Post a Comment

Popular posts from this blog

Global Weight Management Market Size, Share, Analysis, Growth, Forecasts, Trends, Developments & Scope by 2027

In an era, where health and wellness have become paramount, the weight management market has experienced a significant transformation. The Weight Management Market Research Report for 2023 unveils key insights into the latest trends, innovations, and challenges facing this dynamic sector. As individuals across the globe become more conscious of their health and weight, the market is evolving to meet their diverse needs. This report provides a comprehensive overview of the weight management industry, highlighting the factors driving its growth, emerging market segments, and the strategies employed by key players to stay ahead in this competitive landscape. Growing Obesity Rate Across the World: Weight Management Market The report begins by addressing the pressing issue of the global obesity epidemic. With a focus on the alarming statistics and the societal implications of this health crisis, it establishes the context in which the weight management market operates. The report delves in...
Read more

Global Genomics Market Report Reveals Rapid Growth & Transformative Trends in the Genomic Industry by 2027

In the ever-evolving landscape of healthcare, genomics is making headlines for its groundbreaking contributions to personalized medicine, disease understanding, and advancements in pharmaceutical research. The Global Genomics Market Report for 2023 highlights the impressive growth and transformative trends within the genomics industry, shedding light on the exciting potential of genomics in shaping the future of healthcare. I. The Genomics Market Landscape The report's comprehensive analysis of the global genomics market reveals a dynamic and rapidly expanding landscape. With a CAGR of over [X]% during the forecast period, the industry is experiencing unprecedented growth. Key factors driving this growth include increased adoption of genomics in clinical diagnostics, expanding genomics research initiatives, and the development of advanced sequencing technologies. II. Personalized Medicine Revolution One of the most exciting trends highlighted in the report is the integration of ge...
Read more

Global ATMPs Consulting Market Research Report 2027 - Competitive Analysis by Size, Share, Access, Growth, Demand & Industry Solutions

Advanced therapy medicinal products (ATMPs) are medicines for human utilization which are based on genes, tissues, or cells. They provide revolutionary and novel opportunities for the treatment of diseases and injuries. ATMPs primarily target diseases with unfulfilled medical demands. It has an extensive therapeutic potential for treating multiple types of diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases. Development Complexities and Regulatory Adaptations Drives the ATMPs Consulting Market Growth The development of ATMPs is a complex manufacturing process resulting from handling living tissues or generating GMOs. The huge variety of ATMPs and their inherent complexity offers analytical development challenges. Specific characterization, potency, purity, and identity assays are needed for each product. Evolving regulatory needs for ATMPs in developed regions such as EU and U.S. and the need to meet demanding regulatory expectations pose various regulator...
Read more